WifOR study: How can new treatment options reduce the socioeconomic impact of migraine?
Pounding headaches, nausea, hypersensitivity to light: migraine is a serious neurological disease affecting around 15.5 million people in Germany. The disease not only limits the quality of life of those affected, but also has real economic consequences: Socioeconomic losses due to migraine are 100.4 billion euros annually – an average of 6,493 euros per patient in Germany alone.
„Drugs that inhibit so-called Calcitonin Gene-Related Peptides (CGRP) have the potential to prevent about 166 million migraine days in Germany“, says Prof. Dr. Dennis Ostwald, WifOR Managing Director and Head of Health Economics. „This corresponds to nearly 340 million paid and unpaid working hours per year and a potentially avoided productivity loss of 27 billion euros.“ The study „The Social Impact of prophylactic migraine treatments in Germany – A state transition and open cohort approach“ shows that for every Euro spent on CGRP therapies, 3.16 Euros are generated in the form of Social Impact. The WifOR study was commissioned by Novartis and published in the October 2021 edition of the renowned journal „Value in Health“.
About the study:
The data on headache incidence comes from a population-based longitudinal study, while the data on the effectiveness of new treatment alternatives is based on several clinical trials. Calculations on the prevalence of migraine are based on data from the Global Burden of Disease Collaborative Network. The monetary value of paid lost-time hours was calculated using industry standard values, and unpaid lost-time hours were calculated using the nearest market substitute activity. Economic value chain effects are based on so-called value chain multipliers.
The economic research institute and international think tank WifOR was founded in 2009 as a spin-off from the Technical University of Darmstadt, Germany and conducts research on the health economy, international social policy, sustainability, innovations, and global value chains. WifOR’s clients include international companies, associations, governments, and NGOs. It is based in Darmstadt and Berlin, Germany and has offices in Greece, Ireland, Latin America, and the USA.
Contact for scientific information:
Team Lead Health Economics
+49 6151 5015 517
Ahmed H. Seddik, Claudio Schiener, Dennis A. Ostwald, Sara Schramm, Jasper Huels and Zaza Katsarava (2021). The Social Impact of prophylactic migraine treatments in Germany – A state transition and open cohort approach. Value in Health. 24(10), 1446-1453. DOI: 10.1016/j.jval.2021.04.1281 (Preprint: https://www.valueinhealthjournal.com/action/showPdf?pii=S1098-3015%2821%2901535-7).